Stryker Corporation (NYSE:SYK) reported strong second-quarter 2026 operating results with consolidated net sales rising 9.4% to $6.6 billion, driven by organic growth across its MedSurg and Neurotechnology segments. The company highlighted a resilient recovery from a previously reported cyber incident, citing regained momentum in sales,...
Stryker Corp. (SYK) reported first-quarter earnings that exceeded Wall Street expectations, driven by strong revenue and profit performance. The Kalamazoo, Michigan-based medical device manufacturer posted a quarterly profit of $592 million, translating to $1.54 per share on the reported basis. On an adjusted basis, which...
MedSurg and Neurotechnology: $3.21 billion (ticker SYK) CEO Kevin Lobo confirmed that a significant cyberattack in mid-March 'meaningfully' impacted Stryker's first-quarter 2023 financial results, though the company maintained its full-year guidance for organic sales growth between 8% and 9.5% and adjusted earnings per share of...
Stryker Corporation reported strong second-quarter results with 9% organic sales growth and adjusted earnings per share of $3.69, representing a 17.9% year-over-year increase. The company achieved record installations for its Mako robotic system and saw high-single-digit growth in its MedSurg, Neurotechnology, and Orthopaedics segments as...
Fisher Asset Management LLC reduced its stake in Stryker Corporation (NYSE: SYK) by 5.8% during the fourth quarter, selling 192,839 shares and retaining a position valued at approximately $1.10 billion. This move coincides with Stryker's recent quarterly earnings miss, where the company reported EPS of...
Stryker Corporation (SYK) reported exceptional Q4 results with 11% organic sales growth, capping a year where revenues surpassed $25 billion for the first time. This marks the fourth consecutive year of double-digit expansion for the medical device giant. The company's standout performer was its Mako...
Stryker (NYSE: SYK) unveiled a suite of new orthopaedic innovations at the AAOS 2026 Annual Meeting in New Orleans, reinforcing its commitment to advancing care across multiple specialties. Key highlights include the commercial launch of Triathlon Gold, the first femoral component utilizing additive manufacturing and...
Andra AP fonden significantly increased its position in Stryker Corporation (NYSE:SYK) by 30.2% in the first quarter, purchasing an additional 15,095 shares to hold a total of 65,055 shares valued at $21.4 million. This move aligns with several other institutional investors who recently established new...
Bank of New York Mellon Corp reduced its stake in Stryker Corporation (NYSE:SYK) by 8.3% in the first quarter, selling 359,418 shares to hold a remaining position of 3,952,401 shares valued at approximately $1.3 billion. While BNY Mellon decreased its holding, several other institutional investors...
Stryker Corporation (SYK) is a global medical technology leader specializing in orthopedic implants, surgical equipment, and hospital infrastructure. Its diverse portfolio includes hip and knee replacement systems, trauma devices, spine products, endoscopic instruments, patient mobility solutions, and robotic-assisted surgery platforms like Mako. The company operates...
Stryker Corporation (SYK) is a global medical technology leader with a market cap of $118.4 billion, operating in Orthopaedics, MedSurg, and Neurotechnology. Despite facing an unexpected cyber disruption that impacted first-quarter results, the company maintains strong underlying demand, a robust capital order book, and significant...
Stryker has officially completed its acquisition of Amplitude Vascular Systems, a privately held medical technology firm based in Boston that specializes in treating severely calcified arterial disease. This deal marks a significant strategic milestone for Stryker as it seeks to expand its peripheral vascular portfolio...
Stryker, a major medical supply company based in Portage, Michigan, announced that its systems were disrupted by a cyberattack believed to have originated from Iran. The company stated that the incident is contained and does not believe ransomware or malware has entered their systems. Stryker...
Stryker (NYSE: SYK) reported a strong second quarter on July 30, with total sales rising 9.4% to $6.6 billion and reported EPS surging 44.1% to $3.30. This performance marks a significant recovery following a recent cyber incident that had previously disrupted operations. CEO Kevin Lobo...
Stryker Corporation (NYSE:SYK) maintains a consensus 'Moderate Buy' rating from twenty-three brokerages, with sixteen analysts issuing buy ratings and six holding the stock. The average twelve-month price target stands at $392.52, though recent reports show mixed sentiment; Argus set a $370 target in late July,...
AIA Group Ltd reduced its stake in Stryker Corporation (NYSE:SYK) by 8.4% in the first quarter, selling 1,624 shares to hold a remaining position of 17,738 shares valued at $5.829 million. While AIA decreased its holdings, several other institutional investors including Sankala Group LLC, Godfrey...
Atlas Wealth LLC established a new position in Stryker Corporation (NYSE:SYK) during the first quarter, purchasing 36,760 shares valued at approximately $12.08 million. This investment represents 1.5% of Atlas Wealth's portfolio and ranks as its 19th largest holding. Several other institutional investors also adjusted their...
This article evaluates Stryker Corporation (NYSE: SYK) as a top medical device stock, ranking it ninth on a list of elite hedge fund picks. The analysis highlights the broader medical device market's projected growth to $955.49 billion by 2030, driven by an aging global population...
AMG National Trust Bank increased its stake in Stryker Corporation (NYSE:SYK) by 18.9% during the first quarter, purchasing an additional 2,927 shares to hold a total of 18,422 shares valued at $6.053 million according to SEC filings. Several other institutional investors including VanderPol Investments, KCM...
Raymond James upgraded Stryker (NYSE: SYK) to an Outperform rating with a $418 price target, citing the company as a high-quality large-cap MedTech stock. The firm notes that while Stryker has achieved double-digit sales growth for five consecutive years, its valuation multiple appears compressed, suggesting...
